Peregrine Pharmaceuticals reported $429.84M in Assets for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Agenus AGEN:US $ 456.17M 14.87M
Amgen AMGN:US $ 59294M 98M
AstraZeneca AZN:LN 96579M 3694M
Biocryst Pharmaceuticals BCRX:US $ 510.54M 17.18M
Bristol Myers Squibb BMY:US $ 100357M 2677M
Celldex Therapeutics CLDX:US $ 402.96M 21.08M
Chemocentryx CCXI:US $ 419.39M 21.06M
Eli Lilly And LLY:US $ 47063.6M 144.3M
GlaxoSmithKline GSK:LN 89045M 644M
Immunogen IMGN:US $ 422.3M 59.41M
Intrexon XON:US $ 321.22M 14.34M
Karyopharm Therapeutics KPTI:US $ 256.48M 37.56M
Macrogenics MGNX:US $ 218.04M 53.4M
Mannkind MNKD:US $ 285.8M 22.52M
Minerva Neurosciences NERV:US $ 64.96M 5.66M
Newlink Genetics NLNK:US $ 93.19M 7.12M
Novartis NOVN:VX SF 122910M 2308M
Novavax NVAX:US $ 2622.99M 211.88M
Peregrine Pharmaceuticals PPHM:US $ 429.84M 115.75M
Repligen RGEN:US $ 2444.92M 61.09M
Xencor XNCR:US $ 851.32M 6.6M